Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.
The price of Hims & Hers Health Inc (NYSE: HIMS) closed at $42.79 in the last session, down -3.60% from day before closing price of $44.39. In other words, the price has decreased by -$3.60 from its previous closing price. On the day, 60.86 million shares were traded. HIMS stock price reached its highest trading level at $48.3399 during the session, while it also had its lowest trading level at $42.4.
Ratios:
We take a closer look at HIMS’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.36 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 83.31. For the most recent quarter (mrq), Quick Ratio is recorded 1.64 and its Current Ratio is at 1.88. In the meantime, Its Debt-to-Equity ratio is 1.92 whereas as Long-Term Debt/Eq ratio is at 1.92.
Needham reiterated its Buy rating for the stock on June 04, 2025, while the target price for the stock was revised from $61 to $65.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Oct 27 ’25 when Boughton Soleil sold 2,637 shares for $50.10 per share. The transaction valued at 132,114 led to the insider holds 158,493 shares of the business.
Boughton Soleil bought 2,637 shares of HIMS for $132,114 on Oct 27 ’25. On Oct 17 ’25, another insider, Okupe Oluyemi, who serves as the Chief Financial Officer of the company, sold 11,592 shares for $57.13 each. As a result, the insider received 662,222 and left with 70,232 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HIMS now has a Market Capitalization of 9671377920 and an Enterprise Value of 9932782592. As of this moment, Hims’s Price-to-Earnings (P/E) ratio for their current fiscal year is 79.11, and their Forward P/E ratio for the next fiscal year is 57.55. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.58. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.37 while its Price-to-Book (P/B) ratio in mrq is 16.76. Its current Enterprise Value per Revenue stands at 4.933 whereas that against EBITDA is 62.02.
Stock Price History:
The Beta on a monthly basis for HIMS is 2.40, which has changed by 0.8953886 over the last 52 weeks, in comparison to a change of 0.15566266 over the same period for the S&P500. Over the past 52 weeks, HIMS has reached a high of $72.98, while it has fallen to a 52-week low of $19.15. The 50-Day Moving Average of the stock is -16.77%, while the 200-Day Moving Average is calculated to be -8.09%.
Shares Statistics:
According to the various share statistics, HIMS traded on average about 29.05M shares per day over the past 3-months and 21795360 shares per day over the past 10 days. A total of 219.12M shares are outstanding, with a floating share count of 203.00M. Insiders hold about 10.19% of the company’s shares, while institutions hold 77.87% stake in the company. Shares short for HIMS as of 1760486400 were 66883420 with a Short Ratio of 2.30, compared to 1757894400 on 66534489. Therefore, it implies a Short% of Shares Outstanding of 66883420 and a Short% of Float of 36.67.
Earnings Estimates
. The current assessment of Hims & Hers Health Inc (HIMS) involves the perspectives of 10.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is $0.18, with high estimates of $0.3 and low estimates of $0.11.
Analysts are recommending an EPS of between $0.58 and $0.4 for the fiscal current year, implying an average EPS of $0.5. EPS for the following year is $0.69, with 12.0 analysts recommending between $1.37 and $0.33.
Revenue Estimates
According to 11 analysts,. The current quarter’s revenue is expected to be $617.56M. It ranges from a high estimate of $624.72M to a low estimate of $608.22M. As of. The current estimate, Hims & Hers Health Inc’s year-ago sales were $481.14MFor the next quarter, 11 analysts are estimating revenue of $661.29M. There is a high estimate of $673.8M for the next quarter, whereas the lowest estimate is $639.25M.
A total of 14 analysts have provided revenue estimates for HIMS’s current fiscal year. The highest revenue estimate was $2.35B, while the lowest revenue estimate was $2.33B, resulting in an average revenue estimate of $2.35B. In the same quarter a year ago, actual revenue was $1.48BBased on 13 analysts’ estimates, the company’s revenue will be $2.81B in the next fiscal year. The high estimate is $3.02B and the low estimate is $2.61B.
